Point-by-Point Progress: Gonorrhea Point of Care Tests

References

• Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence, 2016. Bull World Health Organ. 2019;97(8):548–562.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Sexually transmitted disease surveillance, 2018. U.S. Department of Health and Human Services; 2019, CDC, Atlanta, GA, USA. p. 1–176.
   Google Scholar
• Hook E, Handsfield H. Gonococcal infections in the adult. Sexually transmitted diseases. 4th ed. New York: McGraw-Hill; 2007. p. 627–645.
   Google Scholar
• Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1 AIDSCAP Malawi Research Group. Lancet. 1997;349:1868–1873.
   PubMed Web of Science ®Google Scholar
• Unemo M, Del Rio C, Shafter WM. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr. 2016;4(3):EI10-0009-2015.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and prevention (CDC). Antibiotic resistance threats in the united states, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
   Google Scholar
• Tabrizi SN, Unemo M, Limnios AE, et al. Evaluation of six commercial nucleic acid amplification tests for detection of Neisseria gonorrhoeae and other Neisseria species. J Clin Microbiol. 2011;49(10):3610–3615.
   PubMed Web of Science ®Google Scholar
• Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15(1):364–378.
   PubMedGoogle Scholar
• Wi T, Lahra MM, Ndowa F, et al. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med. 2017;14(7):e1002344.
   PubMed Web of Science ®Google Scholar
• Sadiq ST, Mazzaferri F, Unemo M. Rapid accurate point-of-care tests combining diagnostics and antimicrobial resistance prediction for Neisseria gonorrhoeae and Mycoplasma genitalium. Sex Transm Infect. 2017;93(S4):S63–S68.
   Google Scholar
• Allan-Blitz LT, Wang X, Klausner JD. Wild-Type Gyrase A Genotype of Neisseria gonorrhoeae Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis. Sex Transm Dis. 2017;44(5):261–265.
   PubMed Web of Science ®Google Scholar
• Allan-Blitz LT, Humphries RM, Hemarajata P, et al. Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of Neisseria gonorrhoeae in a large health system. Clin Infect Dis. 2017;64(9):1268–1270.
   PubMed Web of Science ®Google Scholar
• Allan-Blitz LT, Hemarajata P, Humphries RM, et al. Ciprofloxacin may be efficacious in treating wild-type gyrase a genotype Neisseria gonorrhoeae infections. Sex Transm Dis. 2018;45(4):e18.
   PubMed Web of Science ®Google Scholar
• Melendez JH, Hardick J, Barnes M, et al. Antimicrobial Susceptibility of Neisseria gonorrhoeae isolates in Baltimore, Maryland, 2016: the importance of sentinel surveillance in the era of multi-drug-resistant gonorrhea. Antibiotics (Basel). 2018;7(3):77–83.
   Web of Science ®Google Scholar
• Melendez JH, Hsieh YH, Barnes M, et al. Can ciprofloxacin be used for precision treatment of gonorrhea in public STD clinics? Assessment of ciprofloxacin susceptibility and an opportunity for point-of-care testing. Pathogens. 2019;8(4):189–194.
   PubMed Web of Science ®Google Scholar
• Gift TL, Pate M, Hook IEW, et al. The rapid test paradox: when fewer cases detected lead to more cases treated, a decision analysis of tests for Chlamydia trachomatis. Sex Trans Dis. 1999;26(4):232–240.
   PubMed Web of Science ®Google Scholar
• Hsieh YH, Gaydos CA, Hogan MT, et al. What qualities are most important to making a point of care test desirable for clinicians and others offering sexually transmitted infection testing? PLoS One. 2011;6(4):e19263.
   PubMed Web of Science ®Google Scholar
• Peeling RW, Holmes KK, Mabey D, Peeling RW, Holmes KK, Mabey D, et al. Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect. 2006;82(Suppl 5):v1–6.
   PubMed Web of Science ®Google Scholar
• Pai NP, Vadnais C, Denkinger C, et al. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 2012;9(9):e1001306.
   PubMed Web of Science ®Google Scholar
• Pai M, Ghiasi M, Pai NP. Point-of-care diagnostics testing in global health: what is the point? Microbe. 2015;10:103–107.
   Google Scholar
• Rompalo AM, Hsieh YH, Hogan T, et al. Point-of-care tests for sexually transmissible infections: what do ‘end users’ want? Sex Health. 2013;10(6):541–545.
   PubMed Web of Science ®Google Scholar
• Wi TE, Ndowa FJ, Ferreyra C, et al. Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward. J Int AIDS Soc. 2019;30(Suppl 6):e25343.
   PubMedGoogle Scholar
• Toskin I, Murtagh M, Peeling RW, et al., Advancing prevention of sexually transmitted infections through point-of-care testing: target product profiles and landscape analysis. Sex Transm Infect. 2017;93(S4): S69–S80.
   PubMedGoogle Scholar
• Huppert JS, Hesse E, Gaydos CA. What’s the point? How point-of-care sexually transmitted infection tests can impact infected patients. Point Care. 2010;9(1):36–46.
   PubMedGoogle Scholar
• Watchers-Smith LA, Hillman R, Ward J, et al. Point-of-care tests for the diagnosis of Neisseria gonorrhoeae infection: a systematic review of operational and performance characteristics. Sex Transm Infect. 2013;89(4):320–326.
   PubMed Web of Science ®Google Scholar
• Herbst de Cortina S, Bristow CC, Joseph Davey D, Klausner JD. A systematic review of point of care testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Infect Dis Obstet Gynecol. 2016;20:4386127.
   Google Scholar
• Guy RJ, Causer LM, Klausner JD, et al. Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. Sex Transm Infect. 2017;93(S4):S16–S21.
   PubMedGoogle Scholar
• Gaydos C, Hardick J. Point of care diagnostics for sexually transmitted infections: perspectives and advances. Expert Rev Anti Infect Ther. 2014;12(6):657–672.
   PubMed Web of Science ®Google Scholar
• Cristillo AD, Bristow CC, Peeling R, et al. Point-of-care sexually transmitted infection diagnostics: proceedings of the Star sexually transmitted infection-clinical trial group programmatic meeting. Sex Transm Dis. 2017;44(4):211–218.
   PubMed Web of Science ®Google Scholar
• Donà V, Low N, Golparian D, et al. Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae. Expert Rev Mol Diagn. 2017;17(9):845–859.
   PubMed Web of Science ®Google Scholar
• Unemo M, Seifert HS, Hook EW 3rd, et al., Gonorrhoea. Nat Rev Dis Primers. 2019;5(1): 79–102.
   PubMedGoogle Scholar
• Gaydos CA, Van Der Pol B, Jett-Goheen M, et al. Performance of the Cepheid CT/NG X-pert rapid PCR test for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol. 2013;51(6):1666–1672.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Unemo M, Golparian D, et al. Analytical Evaluation of GeneXpert CT/NG, the First Genetic Point-of-Care Assay for Simultaneous Detection of Neisseria gonorrhoeae and Chlamydia trachomatis. J Clin Microbiol. 2013;51(6):1945–1947.
   PubMed Web of Science ®Google Scholar
• Jacobsson S, Boiko I, Golparian D, et al. WHO laboratory validation of Xpert® CT/NG and Xpert® TV on the GeneXpert system verifies high performances. APMIS. 2018;126(12):907–912.
   PubMed Web of Science ®Google Scholar
• Harding-Esch EM, Nori AV, Hegazi A, et al. Impact of deploying multiple point-of-care tests with a ‘sample first’ approach on a sexual health clinical care pathway A service evaluation. Sex Transm Infect. 2017;93(6):424–429.
   PubMed Web of Science ®Google Scholar
• Gaydos CA, Ako M-C, Lewis M, et al., Use of a rapid diagnostic for Chlamydia trachomatis and Neisseria gonorrhoeae for women in the emergency department can improve clinical management: report of a randomized clinical trial. Ann Emerg Med. 2019;74(1): 36–44.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (FDA). [cited 2020 Feb 8]. Available from: https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea, accessed  02-08-20.
   Google Scholar
• Dize L, Silver B, Gaydos C. Comparison of the Cepheid GeneXpert CT/NG assay to the hologic aptima combo 2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in self-collected rectal swabs. Diagn Microbiol Infect Dis. 2018;90(2):83–84.
   PubMed Web of Science ®Google Scholar
• Danby CS, Cosentino LA, Rabe LK, et al. Patterns of extragenital chlamydia and gonorrhea in women and men who have sex with men reporting a history of receptive anal intercourse. Sex Transmit Dis. 2016;43(2):105–109.
   PubMed Web of Science ®Google Scholar
• Badman SG, Willie B, Narokobi R, et al. A diagnostic evaluation of a molecular assay used for testing and treating anorectal chlamydia and gonorrhoea infections at the point-of-care in Papua New Guinea. Clin Micro Infect. 2019;25(5):623–627.
   PubMed Web of Science ®Google Scholar
• Goldenberg SD, Finn J, White JA, et al. Performance of the GenExpert CT/NG assay compared to that of the aptima AC2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of residual Aptima samples. J Clin Microbiol. 2012;50(12):3867–3869.
   PubMed Web of Science ®Google Scholar
• Bristow CC, Morris SR, Little SJ, et al., Meta-analysis of the Cepheid Xpert® CT/NG assay for extragenital detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections. Sex Health. 2019;16(4): 314–319.
   PubMed Web of Science ®Google Scholar
• Dize L, West SK, Mkocha H, et al. Evaluation of pooled ocular and vaginal swabs by the Cepheid GeneXpert CT/NG assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae as compared to the Aptima Combo 2 Assay. Diagn Microbiol Infect Dis. 2015;81(2):102–104.
   PubMed Web of Science ®Google Scholar
• Speers DJ, Chua IJ, Manuel J, et al. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis from pooled rectal, pharyngeal and urine specimens in men who have sex with men. Sex Transm Infect. 2018;94(4):293–297.
   PubMed Web of Science ®Google Scholar
• Badman SG, Bell SFE, Dean JA, et al. Reduced sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near the point of care. Sex Health. 2020;17(1):15–21.
   PubMed Web of Science ®Google Scholar
• Van Der Pol B, Taylor SN, Mena L, et al. Evaluation of the Performance of a Point-of-Care Test for Chlamydia and Gonorrhea. JAMA Network Open. 2020;3(5):e204819.
   PubMed Web of Science ®Google Scholar
• https://genomeweb.com/pcr/after-years-groundwork-rapid-sti-mdx-space-inaugurated-bins0fds-clearance#XWVITONKjAU. Accessed 2019 Aug 27.
   Google Scholar
• Widdice LE, Hsieh Y-H, Silver B, et al. Performance of the atlas genetics rapid test for Chlamydia trachomatis and womenʼs attitudes toward point-of-care testing. Sex Transm Dis. 2018;45(11):723–727.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Tan LY, Walker S, et al. Multiplex assay for simultaneous detection of Mycoplasma genitalium and macrolide resistance using PlexZyme and Plexprime technology. PLoS One. 2016;11(6):e0156740.
   PubMed Web of Science ®Google Scholar
• Ebeyan S, Windsor M, Bordin A, et al. Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae. J Antimicrob Chemother. 2019;74(7):1820–1824.
   PubMed Web of Science ®Google Scholar
• Drud S, Mjuguna P, Ebeyan S, et al. Evaluation of the resistanceplus Mg flexible assay for detection of wild-type and 23s rRNA-Mutated Mycoplasma genitalium Strains. J Clin Microbiol. 2020;58(3):pii: e01900-19.
   PubMed Web of Science ®Google Scholar
• Sweeney EL, Mhango LP, Ebeyan S, et al. Evaluation of the resistanceplus mg flexible cartridge for near-point-of-care testing of Mycoplasma genitalium and associated macrolide resistance mutations. J Clin Microbiol. 2020;58(3):pii: e01897-19.
   PubMed Web of Science ®Google Scholar
• Shin DJ, Athamanolap P, Chen L, et al. Mobile nucleic acid amplification testing (mobiNAAT) for Chlamydia trachomatis screening in hospital emergency department settings. Sci Rep. 2017;7(1):4495–4499.
   PubMedGoogle Scholar
• Shin DJ, Trick AY, Hsieh Y-H, et al. Sample-to-answer droplet magnetofluidic platform for point-of-care hepatitis C viral load quantitation. Sci Rep. 2018;8(1):9793–9804.
   PubMedGoogle Scholar
• Trick A, Melendez J, Chen L, et al. Point-of-care magnetofluidic assay cartridge for Neisseria gonorrhoeae detection and antimicrobial resistance determination. Sex Transm Infect. 2019;95(Suppl 1):A46.
   PubMedGoogle Scholar
• Harding-Esch EM, Fuller SS, Chow SC, et al. Diagnostic accuracy of a prototype rapid chlamydia and gonorrhoea recombinase polymerase amplification assay: a multicentre cross-sectional preclinical evaluation. Clin Microbiol Infect. 2019;25(3):e1–380.e7.
   PubMed Web of Science ®Google Scholar
• Joda H, Pais R, Pais A. IEEE Ann. Meeting NIH, Bethesda MD, Nov 21-22, 2019.
   Google Scholar
• Hui BB, Wilson DP, Ward JS, et al. The potential impact of new generation molecular point-of-care tests on gonorrhoea and chlamydia in a setting of high endemic prevalence. Sex Health. 2013;10(4):348–356.
   PubMed Web of Science ®Google Scholar
• Rönn MM, Menzies NA, Gift TL, et al., Potential for point-of-care tests to reduce chlamydia associated burden in the United States: a mathematical modeling analysis. Clin Infect Dis. 2020;70(9): 1816–1823.
   PubMed Web of Science ®Google Scholar
• Rönn MM, Testa C, Tuite AR, et al. The potential population-level impact of different gonorrhea screening strategies in Baltimore and San Francisco: an exploratory mathematical modeling analysis. Sex Transm Dis. 2020;47(3):143–150.
   PubMed Web of Science ®Google Scholar
• Van Der Pol B. Making the most of point-of-care testing for sexually transmitted diseases. Clin Infect Dis. 2020;70:1824–1825.
   PubMed Web of Science ®Google Scholar
• Turner KME, Round J, Hoener P, et al. An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in England. Sex Transm Infect. 2014;90(2):104–111.
   PubMed Web of Science ®Google Scholar
• Adams EJ, Ehrlich A, Turner KM, et al. Mapping patient pathways and estimating resource use for point of care versus standard testing and treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UK. BMJ Open. 2014;4(7):e005322.
   PubMed Web of Science ®Google Scholar
• Williams SP, Kinsey J, Carry MG, et al. Get in, get tested, get care: STD services in urban urgent care centers. Sex Transm Dis. 2019;46(10):648–653.
   PubMed Web of Science ®Google Scholar
• Gettinger JG, Van Wagoner N, Daniels B, et al. Patients are willing to wait for rapid sexually transmitted infection results in a university student health clinic. Sex Transm Dis. 2020;47(1):67–69.
   PubMed Web of Science ®Google Scholar
• Shin DJ, Lewis M, Hsieh Y-H, et al. Healthcare worker feedback on a prototype smartphone-based point-of-care test platform for use in episodic care. Point of Care. 2018;17(2):63–65.
   PubMed Web of Science ®Google Scholar
• Rompalo AM, Castleberry N, Widdice L, et al. Patterns of point-of-care test use among obstetricians and gynecologists in the United States. Sex Health. 2018;15(4):318–324.
   PubMedGoogle Scholar
• Natoli L, Guy RJ, Shephard M, et al. “I do feel like a scientist at times”: a qualitative study of the acceptability of molecular point-of-care testing for chlamydia and gonorrhoea to primary care professionals in a remote high sti burden setting. PLoS One. 2015;10(12):e0145993.
   PubMed Web of Science ®Google Scholar
• Hsieh Y, Hogan M, Barnes M, et al. Perceptions of an ideal point-of-care test for sexually transmitted infections–a qualitative study of focus group discussions with medical providers. PLoS One. 2010;5(11):e14144.
   PubMed Web of Science ®Google Scholar
• Hsieh Y-H, Gaydos CA, Hogan TM, et al. Perceptions on Point-of-Care Tests for Sexually Transmitted Infections Comparison Between Frontline Clinicians and Professionals in Industry. Point of Care. 2012;11(2):126–129.
   PubMedGoogle Scholar
• Rompalo AM, Hsieh YH, Hogan T, et al. Point-of-care tests for sexually transmissible infections: what do ‘end-users’ want? Sex Health. 2013;10(6):541–545.
   PubMed Web of Science ®Google Scholar
• Garrett N, Mitchev N, Osman F, et al. Diagnostic accuracy of the Xpert CT/NG and OSOM Trichomonas Rapid assays for point-of-care STI testing among young women in South Africa: a cross-sectional study. BMJ Open. 2019;9(2):e026888. 19.
   PubMed Web of Science ®Google Scholar
• Wynn A, Ramogola-Masire D, Gaolebale P, et al. Prevalence and treatment outcomes of routine Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis testing during antenatal care, Gaborone, Botswana. Sex Transmit Infect. 2018;94(3):230–235.
   PubMed Web of Science ®Google Scholar
• Guy RJ, Ward J, Causer LM, et al. Molecular point-of-care testing for chlamydia and gonorrhoea in Indigenous Australians attending remote primary health services (TTANGO): a cluster-randomised, controlled, crossover trial. Lancet Infect Dis. 2018;18(10):1117–1126.
   PubMed Web of Science ®Google Scholar
• Causer LM, Guy RJ, Tabrizi S, et al. Molecular test for chlamydia and gonorrhoea used at point of care in remote primary healthcare settings: a diagnostic test evaluation. Sex Transm Infect. 2018;94(5):340–345.
   PubMed Web of Science ®Google Scholar
• Maduna LD, Kock MM, Medina-Marino A, et al. Impact of specimen storage temperature and time on the implementation of GeneXpert® testing for sexually transmitted infections in resource-constraint settings. J Microbiol Methods. 2019;165:105719.
   PubMed Web of Science ®Google Scholar
• Fingerhuth SM, Low N, Bonhoeffer S, et al. Detection of antibiotic resistance is essential for gonorrhoea point-of-care testing: a mathematical modelling study. BMC Med. 2017;15(1):142–153.
   PubMedGoogle Scholar
• Turner KM, Christensen H, Adams EJ, et al. Analysis of the potential for point-of-care test to enable individualised treatment of infections caused by antimicrobial-resistant and susceptible strains of Neisseria gonorrhoeae: a modelling study. BMJ Open. 2017;7(6):e015447.
   PubMed Web of Science ®Google Scholar
• Tuite AR, Gift TL, Chesson HW, et al., Impact of rapid susceptibility testing and antibiotic selection strategy on the emergence and spread of antibiotic resistance in gonorrhea. J Infect Dis. 2017;216(9): 1141–1149.
   PubMed Web of Science ®Google Scholar
• Abrams AJ, Kirkcaldy RD, Pettus K, et al. A case of decreased susceptibility to ceftriaxone in Neisseria gonorrhoeae in the absence of a mosaic penicillin-binding protein 2 (penA) allele. Sex Transm Dis. 2017;44(8):492–494.
   PubMed Web of Science ®Google Scholar
• Lefebvre B, Martin I, Demczuk W, et al. Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis. 2018;24(2):381–383.
   PubMed Web of Science ®Google Scholar
• Palace SG, Wang Y, Rubin DH, et al. RNA polymerase mutations cause cephalosporin resistance in clinical Neisseria gonorrhoeae isolates. Elife. 2020;9:pii:e51407.
   PubMed Web of Science ®Google Scholar
• Wadsworth CB, Sater MRA, Bhattacharyya RP, et al., Impact of species diversity on the design of rna-based diagnostics for antibiotic resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2019;63(8): e00549–19.
   PubMed Web of Science ®Google Scholar
• Zhao YH, Quin XL, Yang JY, et al. Identification and expression analysis of ceftriaxone resistance-related genes in Neisseria gonorrhoeae integrating RNA-Seq data and qRT-PCR validation. J Glob Antimicrob Resist. 2019;16:202–209.
   PubMed Web of Science ®Google Scholar
• Khazaei T, Barlow JT, Schoepp NG, et al. RNA markers enable phenotypic test of antibiotic susceptibility in Neisseria gonorrhoeae after 10 minutes of ciprofloxacin exposure. Sci Rep. 2018;8(1):11606.
   PubMed Web of Science ®Google Scholar
• Gong Z, Lai W, Liu M, et al. Novel Genes Related to Ceftriaxone Resistance Found among Ceftriaxone-Resistant Neisseria gonorrhoeae Strains Selected In Vitro. Antimicrob Agents Chemother. 2016;60(4):2043–2051.
   PubMed Web of Science ®Google Scholar
• Huddy JR, Ni M, Misra S, et al. Development of the Point-of-Care Key Evidence Tool (POCKET): a checklist for multi-dimensional evidence generation in point-of-care tests. Clin Chem Lab Med. 2019;57(6):845–855.
   PubMed Web of Science ®Google Scholar
• Kip MMA, Hummel JM, Eppink EB, et al. Understanding the adoption and use of point-of-care tests in Dutch general practices using multi-criteria decision analysis. BMC Fam Pract. 2019;20(1):8. 10.
   PubMedGoogle Scholar
• Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance — the Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill. Summ.. 2016;65(7):1–19.
   PubMed Web of Science ®Google Scholar
• Cyr S, Torrone E, Workowski K. As a response to STD treatment guideline updates, have Neisseria gonorrhoeae strains regained susceptibility to ciprofloxacin? Sex Transm Dis. 2018;45(S2):S39.
   PubMedGoogle Scholar
• Day MJ, Spiteri G, Jacobsson S, et al. Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. BMC Infect Dis. 2018;18(1):609–617.
   PubMed Web of Science ®Google Scholar
• George CRR, Enriquez RP, Gatus BJ, et al., Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016. PLoS One. 2019;14(4): e0213312.
   PubMed Web of Science ®Google Scholar
• Kularatne R, Maseko V, Gumede L, et al. Trends in Neisseria gonorrhoeae Antimicrobial Resistance over a Ten-Year Surveillance Period, Johannesburg, South Africa, 2008-2017. Antibiotics (Basel). 2018;7(3):58–68.
   PubMed Web of Science ®Google Scholar
• Mabonga E, Parkes-Ratanshi R, Riedel S, et al. Complete ciprofloxacin resistance in gonococcal isolates in an urban Ugandan clinic: findings from a cross-sectional study. Int J STD AIDS. 2019;30(3):256–263.
   PubMed Web of Science ®Google Scholar